store at low temperature
store at -80°C
Garetosmab (REGN 2477) is A whole-human IgG4 monoclonal antibody that selectively inhibits activin A and acts on COVID-19 44. Garetosmab has potential anti-cancer activity and can be used to study ossifying fibrous dysplasia (FOP) and cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 328.00 | |
5 mg | In stock | $ 863.00 | |
10 mg | In stock | $ 1,370.00 |
Description | Garetosmab (REGN 2477) is A whole-human IgG4 monoclonal antibody that selectively inhibits activin A and acts on COVID-19 44. Garetosmab has potential anti-cancer activity and can be used to study ossifying fibrous dysplasia (FOP) and cancer. |
In vitro | Specifically binding to and blocking signaling of activin proteins containing the inhibin βα subunit (activins A, AB, and AC), garetosmab (REGN 2477) has high affinity and specificity for activins A, AB, and AC in vitro. It does not bind or functionally inhibit other TGF-β family ligands that share the same activin receptor pathways, including activin B, inhibin A, BMP-2, BMP6, BMP9, BMP10, GDF8, and GDF11[1]. |
Synonyms | REGN 2477 |
Molecular Weight | N/A |
CAS No. | 2097125-54-5 |
store at low temperature
store at -80°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Garetosmab 2097125-54-5 Stem Cells TGF-beta/Smad REGN-2477 REGN2477 REGN 2477 inhibitor inhibit